Hospira Targets First U.S. Biosimilar Filing In 2014
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic specialty injectables firm expects to file a biosimilar version of Amgen’s Epogen in the U.S. in late 2014, potentially positioning it for its first U.S. biosimilar launch in late 2015.
You may also be interested in...
FDA Wants Biosimilar Naming Guidance Released Before Approving An Application
The agency’s policy, planning and legislation chief says FDA hopes a draft guidance is released before the first application is reviewed.
As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada
The first biosimilar MAb approval in Canada could mean Korea’s Celltrion and its partner Hospira are getting closer to filing in the U.S.
As They Look To The U.S., Celltrion And Hospira Win Approval For Remicade Biosimilars In Canada
The first biosimilar MAb approval in Canada could mean Korea’s Celltrion and its partner Hospira are getting closer to filing in the U.S.